Cerecor Inc. Receives Fast Track Designation For CERC-301 For The Treatment Of Major Depressive Disorder
11/25/2013 12:35:12 PM
More...
|
Cerecor Inc. Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate
11/8/2013 10:00:47 AM
More...
|
Cerecor Inc. to Present at 12th Annual Biotechnology Industry Organization (BIO) Investor Forum
10/2/2013 7:33:47 AM
More...
|
Cerecor Inc. Raises $6.8 Million in Series A-1 Financing
9/12/2013 7:46:55 AM
More...
|
Cerecor Inc. to Present at Stifel Nicolaus Healthcare Conference
9/3/2013 7:18:45 AM
More...
|
Cerecor Inc. to Present at Wedbush Securities Life Sciences Conference
8/13/2013 6:33:53 AM
More...
|
Cerecor Inc. Granted U.S. Patent for Antitussive FP01
8/9/2013 9:31:30 AM
More...
|
Cerecor Inc. Acquires Rights to NR2B Receptor Antagonist From Merck & Co., Inc. (MRK)
4/19/2013 9:03:55 AM
More...
|
Cerecor Inc. Acquires Rights to Merck & Co., Inc. (MRK) COMT Inhibitors
3/20/2013 7:33:17 AM
More...
|
Cerecor Inc. Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
12/6/2012 10:07:38 AM
More...
|
|